MedTrace Logo

Radioimmunotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage IV Breast Cancer

NCT00004085 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2011-06-22

No results posted yet for this study

Summary

RATIONALE: Radiolabeled monoclonal antibodies can locate tumor cells and deliver tumor-killing substances to them. Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by radioimmunotherapy used to kill tumor cells.

PURPOSE: Phase I/II trial to study the effectiveness of radiolabeled monoclonal antibody therapy plus peripheral stem cell transplantation in treating patients who have stage IV breast cancer.

Conditions

Interventions

BIOLOGICAL

filgrastim

as prescribed by physician

PROCEDURE

autologous bone marrow transplantation

1-2 weeks prior to treatment

PROCEDURE

peripheral blood stem cell transplantation

1-2 weeks prior to treatment

RADIATION

yttrium Y 90 monoclonal antibody MN-14

intravenous infusion over 30 min, single dose

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Garden State Cancer Center at the Center for Molecular Medicine and Immunology

    lead OTHER

Principal Investigators

  • Jack D. Burton, MD · Garden State Cancer Center at the Center for Molecular Medicine and Immunology

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1998-05-31
Primary Completion
2002-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00004085 on ClinicalTrials.gov